Table 6. Sensitivity analyses: Treatment outcomes: Percentage of symptom presence over time (acute and chronic phase) (N = 36)a.
Gp 1: Add on Ayurveda Group, Gp 2: Standard of care group
*Values at 95% Confidence Interval where the level of significance, α= 0.05. a Population with last observation carried forward for 20% of missing values lost to follow-up. b p-values assessed by Chi-square/Fisher’s test over 14 days. c p-values assessed using mixed effects logistic regression with treatment group and time point as covariates, while adjusting for baseline differences with the improvement in response as the outcome.
| Parameters | Baseline | Day 14 | Day 28 | Day 60 | p value between groups over timec | ||||||
| Gp 1 (N = 22) | Gp 2 (N = 14) | Gp 1 (N = 22) | Gp 2 (N = 14) | p value between groups over 14 daysb | Gp 1 (N = 22) | Gp 2 (N = 14) | p value between groups over 28 daysc | Gp 1 (N = 22) | Gp 2 (N = 14) | ||
| Anosmia | 59.10% | 35.70% | 18.20% | 14.30% | 0.029* | 13.60% | 7.10% | 0.036* | 9.10% | 7.10% | 0.045* |
| Tastelessness | 36.40% | 35.70% | 18.20% | 17.10% | 0.609 | 13.60% | 0.00% | 0.048* | 4.50% | 0.00% | 0.427 |
| Cough | 78.60% | 81.80% | 28.60% | 35.90% | 0.633 | 14.30% | 22.70% | 0.648 | 14.30% | 22.70% | 0.176 |
| Shortness of breath | 54.50% | 50.00% | 22.70% | 17.10% | 0.676 | 18.20% | 17.10% | 0.785 | 9.10% | 17.10% | 0.045* |
| General Weakness | 77.30% | 71.40% | 63.60% | 50.00% | 0.809 | 36.40% | 35.70% | 0.899 | 31.80% | 42.90% | 0.859 |
| Headache | 27.30% | 21.40% | 9.10% | 0.00% | 0.693 | 27.30% | 0.00% | 0.788 | 9.10% | 7.10% | 0.998 |
| Confusion | 9.10% | 7.10% | 0.00% | 0.00% | - | 0.00% | 0.00% | - | 4.50% | 0.00% | - |